Navigation Links
Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
Date:8/19/2007

PLYMOUTH MEETING, Pa., Aug. 1 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) today reported that development partner MedImmune, Inc. has initiated a multi-dose, Phase 2a clinical trial with its monoclonal antibody (MAb) targeting interleukin-9 (IL-9) in adults with mild, persistent asthma. The placebo-controlled, dose-escalation study is designed to evaluate the safety and tolerability of multiple doses of the antibody. This trial is the second Phase 2a study currently underway with the MAb, known as MEDI-528. Genaera and MedImmune entered into a collaborative licensing agreement for this program in 2001.

"This study begins another important step in evaluating the potential of the anti-IL-9 antibody as a new, long-term maintenance or controller therapy for symptomatic, persistent asthma," said Jack Armstrong, President and Chief Executive Officer of Genaera. "We are pleased that the anti-IL-9 antibody is progressing through MedImmune's respiratory inflammation pipeline and remain excited to be part of this partnership. Furthermore, we are optimistic that this study will add to the body of clinical and preclinical data supporting development of MEDI-528 as a potential therapy for this very serious and unfortunately all too common disease."

Two previous Phase 1 single-dose, dose-escalation studies have been conducted to evaluate the safety, tolerability and pharmacokinetics of the anti-IL-9 MAb in healthy volunteers. The antibody was well tolerated in both studies. MedImmune is also conducting an ongoing Phase 2a study, initiated in late 2006, to evaluate the efficacy of a single intravenous dose of MEDI-528 and its effect on disease mechanisms in adults with atopic asthma. Plans to initiate a
'/>"/>

SOURCE Genaera Corporation

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014 Adaptive Biotechnologies, a clinical stage diagnostics ... the adaptive immune system, is pleased to announce the ... Officer (CCO). The addition of Brain to the Company,s ... leading global healthcare companies, including Dean Schorno ... Genomic Health and Sean Nolan (CTO) from ...
(Date:9/16/2014)... QPID Health , a leader in clinical intelligence software, ... Boston and their first West Coast location in ... Street in Boston , and will house product ... Southern California office will be located at ... the demands of customers nationwide.  Both new locations will be ...
(Date:9/16/2014)... Sept. 16, 2014  Formex, LLC ("Formex"), ... that Mr. Greg Weilersbacher joined Formex as Director ... Greg Weilersbacher has ... focused expertise in Quality Assurance, Facility Validation, ... Weilersbacher brings to Formex a diverse wealth ...
Breaking Medicine Technology:Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 2Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 3QPID Health Announces Major Office Expansion in Boston and Opens Facility in San Diego 2Greg Weilersbacher Joins Formex, LLC As Director of Quality Assurance and Quality Control 2
... Study Success in Using Virus Enzyme to Treat Mouse ... Be Used to,Prevent Both Ear Infection and Pneumonia in ... -- Parents might one,day give their children a weekly ... them from getting a severe middle ear,infection, based on ...
... the Drug Improves Memory, SARASOTA, Fla., March 22, ... it has received positive,preliminary results in its major ... application for the treatment of Alzheimer's,disease. The clinical ... first human clinical study conducted by a,Florida-based research ...
Cached Medicine Technology:Viral Enzyme Recruited in Fight Against Ear Infection 2Viral Enzyme Recruited in Fight Against Ear Infection 3Sarasota's Roskamp Institute Announces Positive Safety Data in,Human Clinical Study for Alzheimer's Disease 2
(Date:9/16/2014)... Thompson HealthDay Reporter MONDAY, ... strong heart fitness can delay a man,s onset of age-related ... suggests. Blood pressure naturally increases as people grow older ... with strong cardio-fitness don,t start drifting toward high blood pressure ... usually experience the early signs of high blood pressure in ...
(Date:9/16/2014)... A mathematical model that replicates Ebola outbreaks can no ... the current epidemic, finds research conducted by the University ... Warwick Mathematics Institute, developed a model that incorporated data ... , The research, titled Epidemiological Dynamics of Ebola ... when applying the available data from the ongoing 2014 ...
(Date:9/16/2014)... 15, 2014Patients with inoperable, early-stage lung cancer who ... five-year survival rate of 40 percent, according to ... Radiation Oncology,s (ASTRO,s) 56th Annual Meeting. Such a ... conventional RT resulted in poor tumor control for ... an update of RTOG 0236, originally published in ...
(Date:9/16/2014)... YORK, NY (September 16, 2014) The Columbia ... the 2014 Higher Education Excellence in Diversity (HEED) ... and largest diversity-focused publication in higher education. As ... honor recognizing U.S. colleges and universities that demonstrate ... be featured along with 82 other recipients in ...
(Date:9/16/2014)... September 16, 2014. Kessler Foundation researchers have published ... speed in the executive deficits found in individuals ... speed account for executive deficits in multiple sclerosis? ... published online ahead of print on August 18 ... authors are Victoria Leavitt, PhD, of the Manhattan ...
Breaking Medicine News(10 mins):Health News:Blood Pressure Seems to Stay Lower Longer in Fitter Men 2Health News:Blood Pressure Seems to Stay Lower Longer in Fitter Men 3Health News:Ebola outbreak 'out of all proportion' and severity cannot be predicated 2Health News:Long-term results of RTOG 0236 confirm good primary tumor control, positive 5-year survival rates 2Health News:Long-term results of RTOG 0236 confirm good primary tumor control, positive 5-year survival rates 3Health News:Columbia University College of Dental Medicine receives diversity award 2Health News:Columbia University College of Dental Medicine receives diversity award 3Health News:Columbia University College of Dental Medicine receives diversity award 4
... ... of young adults with disabilities and adjusting to college life. , ... Wellesley, MA (PRWEB) Jan. 26, 2010 ... services, announced that its ChildRC.com web site now features a very informative and exciting ...
... , WASHINGTON , Jan. 26 ... Dateline NBC documentary on patients who have insurance but not adequate ... to deal with the lack of legal accountability for insurers and ... , The nonprofit consumer group called upon Obama to close ...
... , WASHINGTON , Jan. 26 The ... nonpartisan individual membership association of state legislators -- congratulates Pennsylvania ... for filing House Bills 2053 and 2179, which protect the ... Baker and Schroder will hold a joint press conference tomorrow at ...
... NC What does evolution a field that often ... with preventing and treating disease in our lifetime? A lot, ... may soon be tested on evolution in medical entrance and ... A collection of articles in the January 26 issue ...
... European Commission consultation on the EU Clinical Trials Directive, ... proposals by its member organisations for adapting the Directive,s ... treatment. Since the implementation of the Directive ... concerned about the detrimental effect it has had, particularly ...
... 2010 A Universit de Montral research team is developing ... brain to stop eating. "Mice deprived of leptin will not ... around," says Mose Bendayan, a pathology professor at the Universit ... protein extensively. Leptin regulates appetite in mammals and its ...
Cached Medicine News:Health News:ChildRC.com Features “Acclimating To College Life In A Wheelchair” 2Health News:Obama: Make Equal Justice for Patients a State of the Union Pledge & Re-establish White House Office of Consumer Affairs 2Health News:Obama: Make Equal Justice for Patients a State of the Union Pledge & Re-establish White House Office of Consumer Affairs 3Health News:Pennsylvania Legislators Stand for Health Care Freedom 2Health News:Pennsylvania Legislators Stand for Health Care Freedom 3Health News:Pennsylvania Legislators Stand for Health Care Freedom 4Health News:Medical students may soon be tested on evolution 2Health News:Medical students may soon be tested on evolution 3Health News:European Cancer Organization supports a revision of the EU Clinical Trials Directive 2Health News:European Cancer Organization supports a revision of the EU Clinical Trials Directive 3Health News:A gimmick-free weight-loss pill in the works 2
... BD Persist contains 70% alcohol and ... unique polymer base, forming a barrier ... a protective environment for the povidone ... most commonly associated with catheter related ...
... Aplicare's Saturated Swabsticks ... open, single-use foil-laminated pouches. ... is saturated with precisely ... solution. Each package is ...
Triad Plus PVP-I Prep Solution has broad-spectrum germicidal action. Povidone Iodine Solution using an innovative one-piece screw cap, Triad Plus bottles are designed specifically to meet the needs o...
... Aplicare's Saturated Swabsticks are packaged ... Each 4 inch Swabstick is saturated ... solution. Each package is terminally sterilized, ... the patient. It acts as a ...
Medicine Products: